Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and generics. Net profit surged 428% to Rs 85 crore, boosted by debt settlement and strategic partnerships for affordable insulin access in the US. The company also inaugurated its first US OSD manufacturing facility and commenced Semaglutide filings.